{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:19:46Z","timestamp":1787779186346,"version":"build-2784847793"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274007"],"award-info":[{"award-number":["82274007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.biomaterials.2026.124492","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:40:37Z","timestamp":1785166837000},"page":"124492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["In vivo engineering of CAR immune cells by nonviral nanoparticles"],"prefix":"10.1016","volume":"336","author":[{"given":"Ke","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haomeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenbo","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7373-2355","authenticated-orcid":false,"given":"Min","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2026.124492_bib1","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2026.124492_bib2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1126\/science.abq6990","article-title":"The future of engineered immune cell therapies","volume":"378","author":"Irvine","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.biomaterials.2026.124492_bib3","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","article-title":"Beyond the blood: expanding CAR T cell therapy to solid tumors","volume":"43","author":"Uslu","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","article-title":"From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy","volume":"23","author":"Pinto","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib6","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib7","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s43018-025-01015-z","article-title":"The landscape of CAR-engineered innate immune cells for cancer immunotherapy","volume":"6","author":"Tsahouridis","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124492_bib8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s13402-025-01056-7","article-title":"State of the art in CAR-based therapy: in vivo CAR production as a revolution in cell-based cancer treatment","volume":"48","author":"Esmaeilzadeh","year":"2025","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.biomaterials.2026.124492_bib10","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/cells9051182","article-title":"Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biomaterials.2026.124492_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.biomaterials.2026.124492_bib12","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3390\/biomedicines11061610","article-title":"Mechanisms of action and limitations of monoclonal antibodies and single chain fragment variable (scFv) in the treatment of cancer","volume":"11","author":"Rodr\u00edguez-Nava","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.biomaterials.2026.124492_bib13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biomaterials.2026.124492_bib14","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.bpj.2023.09.004","article-title":"The physical landscape of CAR-T synapse","volume":"123","author":"Xiong","year":"2024","journal-title":"Biophys. J."},{"key":"10.1016\/j.biomaterials.2026.124492_bib15","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1186\/s12967-025-06857-w","article-title":"Discordant CAR-T cell signaling: implications of divergence from physiological T cell activation","volume":"23","author":"Gonzalez-Garcia","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib16","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-Cell therapy for refractory systemic lupus erythematosus","volume":"395","author":"Wang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1615212","article-title":"Tracing the development of CAR-T cell design: from concept to next-generation platforms","volume":"16","author":"Alsaieedi","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib18","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.ymthe.2025.01.035","article-title":"Engineering resilient CAR T cells for immunosuppressive environment","volume":"33","author":"Khalifeh","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2026.124492_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114145","article-title":"Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits","volume":"43","author":"Frankel","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.biomaterials.2026.124492_bib20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tips.2025.11.001","article-title":"Autologous, allogeneic, in vivo CAR for autoimmune diseases","volume":"47","author":"Li","year":"2026","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124492_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25147743","article-title":"Advancements in personalized CAR-T therapy: comprehensive overview of biomarkers and therapeutic targets in hematological malignancies","volume":"25","author":"Olejarz","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124492_bib23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib24","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.3390\/jcm13113202","article-title":"CAR-T-Cell-Based cancer immunotherapies: potentials, limitations, and future prospects","volume":"13","author":"Choudhery","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib25","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41409-025-02539-9","article-title":"Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma","volume":"60","author":"Canelo-Vilaseca","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.biomaterials.2026.124492_bib26","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib27","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1016\/j.ymthe.2024.09.019","article-title":"Synergistic integration of mRNA-LNP with CAR-engineered immune cells: pioneering progress in immunotherapy","volume":"32","author":"Chen","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2026.124492_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biomaterials.2026.124492_bib29","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","author":"Bot","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2026.124492_bib30","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.biomaterials.2026.124492_bib31","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/cancers13071684","article-title":"Infection complications after lymphodepletion and dosing of chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed\/refractory acute lymphoblastic leukemia or B cell non-hodgkin lymphoma","volume":"13","author":"Korell","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2026.124492_bib32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124492_bib33","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2026.124492_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.32604\/or.2026.076420","article-title":"In Vivo CAR-T therapy for cancer treatment: mechanisms, technological advances, and clinical translation","volume":"34","author":"Hao","year":"2026","journal-title":"Oncol. Res."},{"key":"10.1016\/j.biomaterials.2026.124492_bib36","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41570-025-00768-6","article-title":"Small-molecule control of CAR T cells","volume":"9","author":"Adams","year":"2025","journal-title":"Nat. Rev. Chem"},{"key":"10.1016\/j.biomaterials.2026.124492_bib37","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3390\/cells11121910","article-title":"Application and design of switches used in CAR","volume":"11","author":"G\u0142owacki","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.biomaterials.2026.124492_bib38","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3390\/cells11121974","article-title":"CAR T cell locomotion in solid tumor microenvironment","volume":"11","author":"Nguyen","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.biomaterials.2026.124492_bib39","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124492_bib40","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.3390\/ijms26073206","article-title":"Strategies for altering delivery technologies to optimize CAR therapy","volume":"26","author":"Cao","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124492_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910828","article-title":"Improving CAR T-Cell persistence","volume":"22","author":"Pietrobon","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124492_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867013","article-title":"The past, present, and future of non-viral CAR T cells","volume":"13","author":"Moretti","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib43","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib44","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","article-title":"Accelerating and optimising CAR T-cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib45","article-title":"Cost-effective strategies for CAR-T cell therapy manufacturing","volume":"33","author":"Abdo","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib46","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.biomaterials.2026.124492_bib47","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib48","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13046-024-03179-5","article-title":"In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma","volume":"43","author":"Krug","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124492_bib49","doi-asserted-by":"crossref","first-page":"7424","DOI":"10.7150\/thno.101941","article-title":"Revolutionizing cancer treatment: the emerging potential and potential challenges of in vivo self-processed CAR cell therapy","volume":"14","author":"Lv","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.biomaterials.2026.124492_bib50","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s13402-024-00954-6","article-title":"Targeted gene delivery systems for T-cell engineering","volume":"47","author":"Wang","year":"2024","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib51","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s12967-025-06524-0","article-title":"Optimizing viral transduction in immune cell therapy manufacturing: key process design considerations","volume":"23","author":"Dan","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib52","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/v17060802","article-title":"Progress in pseudotyping lentiviral vectors towards cell-specific gene delivery In vivo","volume":"17","author":"Arduini","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.biomaterials.2026.124492_bib53","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omtm.2022.06.004","article-title":"In vivo generation of CAR T cells in the presence of human myeloid cells","volume":"26","author":"Ho","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biomaterials.2026.124492_bib54","first-page":"5702","article-title":"Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors","volume":"4","author":"Frank","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.biomaterials.2026.124492_bib55","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1671761","article-title":"In vivo generated human CAR T cells eradicate tumor cells","volume":"8","author":"Agarwal","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biomaterials.2026.124492_bib56","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In vivo generation of CAR T cells selectively in human CD4+ lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2026.124492_bib57","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2023-189087","article-title":"Targeted In vivo generation of CAR T and NK cells utilizing an engineered lentiviral vector platform","volume":"142","author":"Andorko","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2026.124492_bib58","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","article-title":"Antibodies to combat viral infections: development strategies and progress","volume":"21","author":"Pantaleo","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2026.124492_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002737","article-title":"Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells","volume":"9","author":"Huckaby","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124492_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124492_bib61","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1182\/blood-2024-208461","article-title":"A phase 1, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed\/refractory CD19+ B-Cell malignancies","volume":"144","author":"Garcia","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2026.124492_bib62","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.molmed.2025.05.011","article-title":"Technologies for chimeric antigen receptor transgene delivery","volume":"31","author":"Xiao","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib63","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.biomaterials.2026.124492_bib64","doi-asserted-by":"crossref","unstructured":"J.I. Andorko, R.M. Russell, B.C. Schnepp, D. Grubaugh, K.F. Mullen, A. Wakabayashi, L.J. Carrington, T. O'Malley, L. Kuri-Cervantes, T.D. Culp, P.R. Johnson, Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation, Mol. Ther. 33 4937-4952. https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.036.","DOI":"10.1016\/j.ymthe.2025.06.036"},{"key":"10.1016\/j.biomaterials.2026.124492_bib65","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00562-25","article-title":"Genome integration of human DNA oncoviruses","volume":"99","author":"Vojtechova","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib66","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2018.04.012","article-title":"Modulation of immune responses in lentiviral vector-mediated gene transfer","volume":"342","author":"Annoni","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib68","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","article-title":"Precision medicine: in vivo CAR therapy as a showcase for receptor-targeted vector platforms","volume":"30","author":"Michels","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2026.124492_bib69","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.3390\/ijms25137333","article-title":"Viral and non-viral systems to deliver gene therapeutics to clinical targets","volume":"25","author":"Taghdiri","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124492_bib70","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.biomaterials.2026.124492_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.biomaterials.2026.124492_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124492_bib73","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","article-title":"Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs","volume":"29","author":"Tomb\u00e1cz","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2026.124492_bib74","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1021\/acs.molpharmaceut.5c00385","article-title":"Recent advances in mRNA-LNP delivery systems for extrahepatic organs: a review","volume":"22","author":"Bai","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biomaterials.2026.124492_bib75","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41570-025-00763-x","article-title":"The impact of chemical reactivity on the quality and stability of RNA-LNP pharmaceuticals","volume":"9","author":"Kova\u010di\u010d","year":"2025","journal-title":"Nat. Rev. Chem"},{"key":"10.1016\/j.biomaterials.2026.124492_bib76","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1039\/D3BM00387F","article-title":"Structural and componential design: new strategies regulating the behavior of lipid-based nanoparticles in vivo","volume":"11","author":"Zhong","year":"2023","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.biomaterials.2026.124492_bib77","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1089\/hum.2024.106","article-title":"Lipid nanoparticles for nucleic acid delivery beyond the liver","volume":"35","author":"Saber","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.biomaterials.2026.124492_bib78","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jconrel.2024.04.022","article-title":"Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies - challenges and opportunities","volume":"370","author":"Simonsen","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2026.124492_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ady6730","article-title":"In vivo generation of CAR myeloid cells through erythrocyte-mediated mRNA delivery for cancer immunotherapy","volume":"18","author":"Nie","year":"2026","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib80","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/acssynbio.4c00589","article-title":"Advances in engineering myeloid cells for cell therapy applications","volume":"14","author":"Freitas","year":"2025","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib81","article-title":"From bench to body: in vivo CAR engineering in the clinic","volume":"6","author":"Li","year":"2025","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.biomaterials.2026.124492_bib82","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12032-025-02928-6","article-title":"Applications of nanoparticles in CAR-T cell therapy: non-viral manufacturing, enhancing in vivo function, and in vivo generation of CAR-T cells","volume":"42","author":"Albalawi","year":"2025","journal-title":"Med. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib83","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adz1722","article-title":"Biodegradable targeted polymeric mRNA nanoparticles enable in vivo CD19 CAR T cell generation and lead to B cell depletion","volume":"12","author":"Jain","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biomaterials.2026.124492_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-026-01656-0","article-title":"CAR-neutrophils produced in vivo to treat glioma","author":"Chang","year":"2026","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.biomaterials.2026.124492_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.celbio.2025.100011","article-title":"Leveraging T cell-specific fusogenicity of HIV for in vivo mRNA delivery to produce human CAR-T cells","volume":"1","author":"Wang","year":"2025","journal-title":"Cell Biomater"},{"key":"10.1016\/j.biomaterials.2026.124492_bib86","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124492_bib87","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/vaccines13080821","article-title":"Harnessing the loop: the perspective of circular RNA in modern therapeutics","volume":"13","author":"Zhao","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.biomaterials.2026.124492_bib88","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2026.2661120","article-title":"Self-amplifying RNA (saRNA) and circular RNA (circRNA) vaccines: progress, evidence gaps, and translational pathways for durable and scalable immunization","volume":"22","author":"Okechukwu Paul-Chima","year":"2026","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.biomaterials.2026.124492_bib89","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1021\/acsbiomaterials.5c00445","article-title":"Nanoparticle-mediated gene therapy in women's health: progress, delivery challenges, and the need for sex, age, and ancestry informed design","volume":"11","author":"Maestas-Olguin","year":"2025","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.biomaterials.2026.124492_bib90","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","article-title":"Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy","volume":"38","author":"Lei","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.biomaterials.2026.124492_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202001812","article-title":"Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery","volume":"10","author":"Ho","year":"2021","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.biomaterials.2026.124492_bib92","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124492_bib93","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41573-023-00827-x","article-title":"Tailor made: the art of therapeutic mRNA design","volume":"23","author":"Metkar","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2026.124492_bib94","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.omtn.2022.01.004","article-title":"Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages","volume":"27","author":"Moradian","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biomaterials.2026.124492_bib95","doi-asserted-by":"crossref","first-page":"8305","DOI":"10.3390\/ijms21218305","article-title":"Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies?","volume":"21","author":"Hosseinkhani","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124492_bib96","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1021\/acsabm.0c01463","article-title":"High-throughput automation of endosomolytic polymers for mRNA delivery","volume":"4","author":"Ulkoski","year":"2021","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.biomaterials.2026.124492_bib97","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.xphs.2021.11.004","article-title":"pH-Dependent phase behavior and stability of cationic Lipid-mRNA nanoparticles","volume":"111","author":"Larson","year":"2022","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.biomaterials.2026.124492_bib98","doi-asserted-by":"crossref","first-page":"15206","DOI":"10.1039\/D3NR02175K","article-title":"Efficient mRNA delivery using lipid nanoparticles modified with fusogenic coiled-coil peptides","volume":"15","author":"Zeng","year":"2023","journal-title":"Nanoscale"},{"key":"10.1016\/j.biomaterials.2026.124492_bib99","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41565-025-01961-w","article-title":"Compact polyethylenimine-complexed mRNA vaccines","volume":"20","author":"Moreno Herrero","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib100","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3390\/vaccines12050528","article-title":"The platform technology approach to mRNA product development and regulation","volume":"12","author":"Skerritt","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.biomaterials.2026.124492_bib101","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01775-23","article-title":"Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses","volume":"15","author":"Wan","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.biomaterials.2026.124492_bib102","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s44222-024-00259-1","article-title":"Engineering circular RNA medicines","volume":"3","author":"Cao","year":"2025","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.biomaterials.2026.124492_bib103","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.720","article-title":"Synthetic circRNA therapeutics: innovations, strategies, and future horizons","volume":"5","author":"Cai","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.biomaterials.2026.124492_bib104","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtn.2022.09.010","article-title":"Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy","volume":"30","author":"Yang","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biomaterials.2026.124492_bib105","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ymthe.2023.11.017","article-title":"Circular mRNA-based TCR-T offers a safe and effective therapeutic strategy for treatment of cytomegalovirus infection","volume":"32","author":"Shen","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2026.124492_bib108","article-title":"Synergically enhanced anti-tumor immunity of in vivo panCAR by circRNA vaccine boosting","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib109","article-title":"Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging","volume":"6","author":"Zhang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib110","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/vaccines11020238","article-title":"Cap-Independent circular mRNA translation efficiency","volume":"11","author":"Deviatkin","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.biomaterials.2026.124492_bib111","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3390\/vaccines11071142","article-title":"Advances in saRNA vaccine research against Emerging\/re-emerging viruses","volume":"11","author":"Liu","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.biomaterials.2026.124492_bib112","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.stem.2026.02.006","article-title":"In Vivo CAR-Tfh cell reprogramming restores tolerance in a mouse model of autoimmune hepatitis","volume":"33","author":"Zheng","year":"2026","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.biomaterials.2026.124492_bib113","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.ai.2024.12.001","article-title":"Plasmid DNA and mRNA delivery: approaches and challenges","volume":"165","author":"Singh","year":"2025","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202103258","article-title":"Nanocomplex-mediated In vivo programming to chimeric antigen Receptor-M1 macrophages for cancer therapy","volume":"33","author":"Kang","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2026.124492_bib115","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/bit.28269","article-title":"Poly (beta-amino ester) as an in vivo nanocarrier for therapeutic nucleic acids","volume":"120","author":"Sadeqi Nezhad","year":"2023","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.biomaterials.2026.124492_bib116","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1021\/acsami.3c14714","article-title":"Development of polymer-lipid hybrid nanoparticles for large-sized plasmid DNA transfection","volume":"16","author":"Maeki","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biomaterials.2026.124492_bib117","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","article-title":"Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo","volume":"350","author":"Zhou","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2026.124492_bib118","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ymthe.2023.01.023","article-title":"DNA transposon mechanisms and pathways of genotoxicity","volume":"31","author":"Bushman","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2026.124492_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1411393","article-title":"Engineering strategies to safely drive CAR T-cells into the future","volume":"15","author":"Rossi","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41578-024-00725-7","article-title":"CRISPR\u2013Cas9 delivery strategies for the modulation of immune and non-immune cells","volume":"10","author":"Alsaiari","year":"2025","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.biomaterials.2026.124492_bib121","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biomaterials.2026.124492_bib122","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biomaterials.2026.124492_bib123","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.biomaterials.2026.124492_bib124","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biomaterials.2026.124492_bib125","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ccell.2022.12.009","article-title":"Base editing screens map mutations affecting interferon-\u03b3 signaling in cancer","volume":"41","author":"Coelho","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biomaterials.2026.124492_bib126","doi-asserted-by":"crossref","DOI":"10.1093\/stcltm\/szaf016","article-title":"Emerging clinical applications of ADAR based RNA editing","volume":"14","author":"Rainaldi","year":"2025","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib127","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adl5800","article-title":"Macrophage-specific in vivo RNA editing promotes phagocytosis and antitumor immunity in mice","volume":"17","author":"Chen","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41596-021-00646-7","article-title":"Applications of and considerations for using CRISPR-Cas9-mediated gene conversion systems in rodents","volume":"17","author":"Grunwald","year":"2022","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.biomaterials.2026.124492_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102666","article-title":"Advancing gene editing therapeutics: clinical trials and innovative delivery systems across diverse diseases","volume":"36","author":"Raigani","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biomaterials.2026.124492_bib143","doi-asserted-by":"crossref","first-page":"120","DOI":"10.34133\/bmef.0120","article-title":"A systematic review of toxicity, biodistribution, and biosafety in upconversion nanomaterials: critical insights into toxicity mitigation strategies and future directions for safe applications","volume":"6","author":"Khan","year":"2025","journal-title":"BME Front."},{"key":"10.1016\/j.biomaterials.2026.124492_bib130","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.bpj.2023.09.004","article-title":"The physical landscape of CAR-T synapse","volume":"123","author":"Xiong","year":"2024","journal-title":"Biophys. J."},{"key":"10.1016\/j.biomaterials.2026.124492_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121339","article-title":"In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift","volume":"281","author":"Kheirolomoom","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2026.124492_bib132","doi-asserted-by":"crossref","first-page":"eadx0368","DOI":"10.1126\/scitranslmed.adx0368","article-title":"Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis","volume":"18","author":"Yashaswini","year":"2026","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib133","article-title":"Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging","volume":"122","author":"Zhang","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biomaterials.2026.124492_bib134","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.stem.2025.07.014","article-title":"Targeting ECM-producing cells with CAR-T therapy alleviates fibrosis in chronic kidney disease","volume":"32","author":"Zhao","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.biomaterials.2026.124492_bib135","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202312038","article-title":"Oxidized mRNA lipid nanoparticles for in situ chimeric antigen receptor monocyte engineering","volume":"34","author":"Mukalel","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.biomaterials.2026.124492_bib136","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","article-title":"Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy","volume":"360","author":"Yang","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2026.124492_bib137","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1021\/acsnano.3c10109","article-title":"mRNA-Laden lipid-nanoparticle-enabled in situ CAR-macrophage engineering for the eradication of multidrug-resistant bacteria in a sepsis mouse model","volume":"18","author":"Tang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2026.124492_bib138","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s43018-025-00950-1","article-title":"An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma","volume":"6","author":"Jing","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124492_bib139","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.ymthe.2025.02.031","article-title":"Presetting CAR-T cells during ex vivo biomanufacturing","volume":"33","author":"Wang","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2026.124492_bib140","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41467-025-67674-9","article-title":"Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy","volume":"17","author":"Gu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124492_bib141","article-title":"CircRNA-based, non-integrated, in vivo panCAR-mediated B cell immune resetting in mouse models and non-human primates","author":"Wang","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.biomaterials.2026.124492_bib142","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202310395","article-title":"Spleen SORT LNP generated in situ CAR T cells extend survival in a mouse model of lymphoreplete B cell lymphoma","volume":"62","author":"\u00c1lvarez-Benedicto","year":"2023","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biomaterials.2026.124492_bib144","article-title":"An overview of nanoparticle protein Corona literature","volume":"19","author":"Hajipour","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.biomaterials.2026.124492_bib145","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109256118","article-title":"On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles","volume":"118","author":"Dilliard","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biomaterials.2026.124492_bib146","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib147","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124492_bib148","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3389\/fimmu.2019.00618","article-title":"Dual role of CD4 in peripheral T lymphocytes","volume":"10","author":"Glatzov\u00e1","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib149","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s41590-023-01510-4","article-title":"CD4+ T cell memory","volume":"24","author":"K\u00fcnzli","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib150","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1021\/acsnano.5b02796","article-title":"Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles","volume":"9","author":"Ramishetti","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2026.124492_bib151","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40364-023-00501-9","article-title":"Biomarkers as targets for CAR-T\/NK cell therapy in AML","volume":"11","author":"Shao","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/j.biomaterials.2026.124492_bib152","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.70025","article-title":"CD7-targeting pro-apoptotic extracellular vesicles: a novel approach for T-cell haematological malignancy therapy","volume":"13","author":"Zhang","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.biomaterials.2026.124492_bib153","first-page":"301","article-title":"Advances in strategies to improve the immunotherapeutic efficacy of chimeric antigen receptor-T cell therapy for lymphoma","volume":"22","author":"Yu","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.biomaterials.2026.124492_bib154","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40364-025-00807-w","article-title":"T cells in cancer: mechanistic insights and therapeutic advances","volume":"13","author":"Pu","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.biomaterials.2026.124492_bib155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1291619","article-title":"Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils","volume":"14","author":"Liang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib156","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.3390\/cancers15102717","article-title":"Anti-tumor strategies by harnessing the phagocytosis of macrophages","volume":"15","author":"Li","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2026.124492_bib157","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","article-title":"A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124492_bib158","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713364","article-title":"CAR-NK cells generated with mRNA-LNPs kill tumor target cells in vitro and In vivo","volume":"24","author":"Golubovskaya","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biomaterials.2026.124492_bib159","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","article-title":"Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions","volume":"10","author":"Zhong","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.biomaterials.2026.124492_bib160","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","article-title":"CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy","volume":"23","author":"Hadiloo","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.biomaterials.2026.124492_bib161","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00262-022-03260-y","article-title":"CAR \u03b3\u03b4 T cells for cancer immunotherapy. Is the field more yellow than green?","volume":"72","author":"Ganapathy","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biomaterials.2026.124492_bib162","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41571-022-00722-1","article-title":"The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy","volume":"20","author":"Mensurado","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib163","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1016\/j.ymthe.2025.08.015","article-title":"From bench to bloodstream: lipid nanoparticles drive on-demand CAR-T cells","volume":"33","author":"June","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2026.124492_bib164","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.7150\/thno.98178","article-title":"Trop2-targeted therapies in solid tumors: advances and future directions","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.biomaterials.2026.124492_bib167","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib168","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1097\/CM9.0000000000003706","article-title":"Innovative strategies for improving CAR-T cell therapy: a nanomedicine perspective","volume":"138","author":"Wang","year":"2025","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.biomaterials.2026.124492_bib169","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1039\/D1TB02818A","article-title":"Targeting the innate immune system with nanoparticles for cancer immunotherapy","volume":"10","author":"Li","year":"2022","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.biomaterials.2026.124492_bib170","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3390\/vaccines12101148","article-title":"Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.biomaterials.2026.124492_bib171","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.biomaterials.2026.124492_bib172","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.3390\/cancers14235983","article-title":"Efficacy, safety, and challenges of CAR T-Cells in the treatment of solid tumors","volume":"14","author":"Chen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2026.124492_bib173","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124492_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121741","article-title":"A robust post-insertion method for the preparation of targeted siRNA LNPs","volume":"620","author":"Swart","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biomaterials.2026.124492_bib175","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1038\/s41467-025-59904-x","article-title":"Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire","volume":"16","author":"Cheloni","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124492_bib176","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878209","article-title":"CAR-T cell performance: how to improve their persistence?","volume":"13","author":"L\u00f3pez-Cantillo","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124492_bib177","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.3390\/molecules29133131","article-title":"Achieving endo\/lysosomal escape using smart nanosystems for efficient cellular delivery","volume":"29","author":"Desai","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.biomaterials.2026.124492_bib178","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202309088","article-title":"Synthetic gene circuits for regulation of next-generation cell-based therapeutics","volume":"11","author":"Teixeira","year":"2024","journal-title":"Adv. Sci."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226005168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226005168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:42:12Z","timestamp":1787776932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961226005168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":174,"alternative-id":["S0142961226005168"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124492","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo engineering of CAR immune cells by nonviral nanoparticles","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124492"}}